81403-68-1 | Alfuzosin hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$16.00	$11.00
5mg	98%	in stock	$20.00	$14.00
10mg	98%	in stock	$25.00	$17.00
25mg	98%	in stock	$32.00	$22.00
50mg	98%	in stock	$42.00	$29.00
100mg	98%	in stock	$75.00	$52.00
250mg	98%	in stock	$183.00	$128.00
1g	98%	in stock	$365.00	$255.00

Description

• Catalog Number: AC36580
• Chemical Name: Alfuzosin hydrochloride
• CAS Number: 81403-68-1
• Molecular Formula: C19H28ClN5O4
• Molecular Weight: 425.9097
• MDL Number: MFCD00879135
• SMILES: COc1cc2nc(nc(c2cc1OC)N)N(CCCNC(=O)C1CCCO1)C.Cl

Computed Properties

• Complexity: 511
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 8
• Undefined Atom Stereocenter Count: 1

Literature

• Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• Effects of alfuzosin with methylprednisolone for spontaneous expulsion and pain control of lower ureteral stone.

  Urological research 20121001

• Alpha-blockers impact stent-related symptoms: a randomized, double-blind, placebo-controlled trial.

  Journal of endourology 20120901

• Statistical approach for assessing the influence of calcium silicate and HPMC on the formulation of novel alfuzosin hydrochloride mucoadhesive-floating beads as gastroretentive drug delivery systems.

  AAPS PharmSciTech 20120901

• Comparison of the effects of four α1-adrenoceptor antagonists on ejaculatory function in rats.

  Urology 20120801

• Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.

  The Kaohsiung journal of medical sciences 20120801

• Alfuzosin for the treatment of storage symptoms suggestive of overactive bladder.

  Expert opinion on pharmacotherapy 20120601

• Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.

  Andrologia 20120501

• Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.

  Journal of pharmacy practice 20120401

• The effect of alpha antagonists on pupil dynamics: implications for the diagnosis of intraoperative floppy iris syndrome.

  American journal of ophthalmology 20120401

• Evaluation of a column classification method using the separation of alfuzosin from its related substances.

  Journal of chromatography. A 20120316

• In vitro and in vivo evaluation of a hydrogel-based prototype transdermal patch system of alfuzosin hydrochloride.

  Pharmaceutical development and technology 20120101

• Chronic pelvic pain syndrome and semen quality of Korean men in their fourth decade.

  Journal of andrology 20120101

• Lipases as catalysts in synthesis of fine chemicals.

  Methods in molecular biology (Clifton, N.J.) 20120101

• Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia.

  International urology and nephrology 20111201

• Effects of pulsed electromagnetic fields on benign prostate hyperplasia.

  International urology and nephrology 20111201

• Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue.

  Urology 20111001

• Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.

  Toxicological sciences : an official journal of the Society of Toxicology 20110901

• Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms.

  The journal of sexual medicine 20110901

• Comparison of alpha-blocker, extracorporeal magnetic stimulation alone and in combination in the management of female bladder outlet obstruction.

  International urogynecology journal 20110701

• Cell membrane chromatography competitive binding analysis for characterization of α1A adrenoreceptor binding interactions.

  Analytical and bioanalytical chemistry 20110701

• Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial.

  International journal of urology : official journal of the Japanese Urological Association 20110701

• Postural hypotension.

  BMJ (Clinical research ed.) 20110616

• Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.

  Urology 20110601

• The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.

  Urology 20110501

• Risk factors for intraoperative floppy iris syndrome: a meta-analysis.

  Ophthalmology 20110401

• Influence of chemical permeation enhancers on transdermal permeation of alfuzosin: an investigation using response surface modeling.

  Drug development and industrial pharmacy 20110401

• Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial.

  Korean journal of urology 20110401

• Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.

  The Journal of urology 20110301

• [Recurrent hepatocellular lesion due to alfuzosin].

  Gastroenterologia y hepatologia 20110201

• [Efficacy of prostatic adenoma treatment with alfusozine depending on sexuality].

  Urologiia (Moscow, Russia : 1999) 20110101

• Efficacy of three different alpha 1-adrenergic blockers and hyoscine N-butylbromide for distal ureteral stones.

  International braz j urol : official journal of the Brazilian Society of Urology 20110101

• Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.

  Prostate cancer and prostatic diseases 20101201

• Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20101201

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• [Our experience with the use of alpha-lithic therapy in the treatment of voiding dysfunction].

  Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica 20101001

• Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand.

  The journal of sexual medicine 20100901

• Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis.

  Dermatology online journal 20100615

• Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT.

  Urology 20100601

• [Alpha-1-blockers (alfuzosin) for obstructive salivary gland diseases].

  Revue de stomatologie et de chirurgie maxillo-faciale 20100601

• Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.

  The Journal of urology 20100501

• Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro.

  European urology 20100401

• An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia.

  International journal of clinical practice 20100201

• The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms.

  Journal of endourology 20091101

• Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.

  The Cochrane database of systematic reviews 20091007

• [Use of alfuzosin for expulsion of stones in the distal third of ureter].

  Actas urologicas espanolas 20091001

• Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

  BJU international 20090801

• Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters.

  Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi 20090801

• Quantitation of alfuzosin hydrochloride in pharmaceutical formulations by RP-HPLC.

  Pakistan journal of pharmaceutical sciences 20090701

• Application of a novel symmetrical shape factor to gastroretentive matrices as a measure of swelling synchronization and its impact on drug release kinetics under standard and modified dissolution conditions.

  The Journal of pharmacy and pharmacology 20090701

• Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090701

• Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.

  Drug metabolism and disposition: the biological fate of chemicals 20090601

• Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones.

  Urology 20090401

• Prostatitis: no benefit of alpha-blockers for chronic prostatitis.

  Nature reviews. Urology 20090401

• Functional screening of adrenergic receptors by measuring intracellular calcium using the FlexStation scanning fluorimeter.

  Biotechnology journal 20090301

• Effect of alfuzosin on female primary bladder neck obstruction.

  International urogynecology journal and pelvic floor dysfunction 20090201

• Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.

  The journal of sexual medicine 20090201

• Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study.

  The Journal of urology 20090101

• Watchful waiting in benign prostatic hyperplasia.

  Current opinion in urology 20090101

• Sexuality and the management of BPH with alfuzosin (SAMBA) trial.

  International journal of impotence research 20090101

• Effects of alfuzosin and tamsulosin on sperm parameters in healthy men: results of a short-term, randomized, double-blind, placebo-controlled, crossover study.

  Journal of andrology 20090101

• Can open-label studies demonstrate efficacy in improving sexual function?

  International journal of impotence research 20090101

• Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.

  Urologia internationalis 20090101

• Alfuzosin hydrochloride transdermal films: evaluation of physicochemical, in vitro human cadaver skin permeation and thermodynamic parameters.

  International braz j urol : official journal of the Brazilian Society of Urology 20090101

• Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

  Reviews in urology 20090101

• [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma].

  Urologiia (Moscow, Russia : 1999) 20090101

• Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.

  The New England journal of medicine 20081218

• Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081215

• Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction.

  BJU international 20081201

• Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.

  Clinical interventions in aging 20080901

• Selective and automated sample pretreatment by molecularly imprinted polymer for the analysis of the basic drug alfuzosin from plasma.

  Journal of chromatography. A 20080704

• Intraoperative floppy-iris syndrome associated with systemic alpha blockers.

  Journal of cataract and refractive surgery 20080701

• Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study.

  The Journal of urology 20080601

• [Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].

  Harefuah 20080601

• Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum.

  The journal of sexual medicine 20080401

• Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.

  BJU international 20080401

• Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles: possible model for intraoperative floppy-iris syndrome.

  Journal of cataract and refractive surgery 20080301

• The concept of neurogenic inflammation.

  BJU international 20080301

• Role of alpha1-blockers in chronic prostatitis syndromes.

  BJU international 20080301

• Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system.

  International journal of pharmaceutics 20080204

• In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs.

  European journal of pharmacology 20080202

• Alfuzosin delays cardiac repolarization by a novel mechanism.

  The Journal of pharmacology and experimental therapeutics 20080201

• Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals.

  International urology and nephrology 20080101

• The effect of various alpha1-adrenergic receptor antagonists on pupillary dilation.

  Annals of ophthalmology (Skokie, Ill.) 20080101

• Human epididymal and prostatic tracts of vas deferens: different contraction response to noradrenaline stimulation in isolated organ bath assay.

  European journal of pharmacology 20071222

• Stability-indicating spectrophotometric and spectrofluorimetric methods for determination of alfuzosin hydrochloride in the presence of its degradation products.

  Die Pharmazie 20071101

• The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract.

  European urology 20070901

• Alfuzosin-induced acute liver injury.

  The Korean journal of hepatology 20070901

• Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.

  The Journal of urology 20070801

• Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum.

  Combinatorial chemistry & high throughput screening 20070801

• Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin.

  Journal of cataract and refractive surgery 20070701

• Selective sample treatment using molecularly imprinted polymers.

  Journal of chromatography. A 20070608

• Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.

  European urology 20070601

• Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?

  European urology 20070601

• Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist.

  American journal of ophthalmology 20070601

• Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20070601

• Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20070601

• The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study.

  Naunyn-Schmiedeberg's archives of pharmacology 20070501

• Re: Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers: W. J. Hellstrom and S. C. Sikka. J Urol 2006; 176: 1529-1533.

  The Journal of urology 20070401

• Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.

  Prostate cancer and prostatic diseases 20070101

• Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.

  International journal of impotence research 20070101

• In vitro controlled release of alfuzosin hydrochloride using HPMC-based matrix tablets and its comparison with marketed product.

  Pharmaceutical development and technology 20070101

• [The experience in postoperative administration of alpha-adrenoblockers].

  Urologiia (Moscow, Russia : 1999) 20070101

• Intraoperative floppy iris syndrome in a patient taking alfuzosin for benign prostatic hypertrophy.

  Eye (London, England) 20061201

• Alfuzosin (10 mg) does not affect blood pressure in young healthy men.

  European urology 20061201

• Molecularly imprinted polymers for the clean-up of a basic drug from environmental and biological samples.

  Journal of chromatography. A 20061201

• Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations.

  Journal of separation science 20061201

• Urethral syndrome: response to alpha-adrenergic blocking agents.

  International urogynecology journal and pelvic floor dysfunction 20061101

• Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats.

  BJU international 20061001

• Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers.

  The Journal of urology 20061001

• Stuttering priapism after ingestion of alfuzosin.

  Urology 20061001

• Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.

  The Journal of urology 20060901

• Toxic epidermal necrolysis caused by alfuzosin, an alpha1-adrenoceptor antagonist.

  Archives of dermatology 20060701

• The management of chronic prostatitis in men with HIV.

  Current urology reports 20060701

• The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.

  BJU international 20060601

• Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.

  Urology 20060601

• The natural history of benign prostatic hyperplasia.

  BJU international 20060401

• Definition of at-risk patients: dynamic variables.

  BJU international 20060401

• Tablet induced dysphagia in oesophageal cancer.

  Gut 20060401

• The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.

  BJU international 20060401

• Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.

  BJU international 20060401

• Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

  Expert opinion on pharmacotherapy 20060401

• Treatment and pharmacologic management of BPH in the context of common comorbidities.

  The American journal of managed care 20060401

• Are all alpha-blockers created the same?

  European urology 20060301

• Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL).

  European urology 20060301

• Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.

  BJU international 20060301

• Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.

  BJU international 20060301

• What's the point?

  BJU international 20060301

• Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.

  International journal of clinical practice 20060301

• Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.

  The Journal of urology 20060201

• In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits.

  Naunyn-Schmiedeberg's archives of pharmacology 20060201

• Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.

  Prostate cancer and prostatic diseases 20060101

• Effects of selective alpha-1-adrenergic receptor blockers on bladder weight.

  Urologia internationalis 20060101

• Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.

  The Journal of urology 20060101

• Is there a role for alpha1-blockers in treating double-J stent-related symptoms?

  Urology 20060101

• Obstructive primary bladder neck disease: evaluation of the efficacy and safety of alpha1-blockers.

  Urologia internationalis 20060101

• Effects of alpha(1)-adrenoceptor antagonists on male sexual function.

  Drugs 20060101

• 'Ejaculatory disorders and alpha1-adrenoceptor antagonists therapy: clinical and experimental researches'.

  Journal of translational medicine 20060101

• [Diagnosis and treatment of urinary bladder dysfunctions in patients with nephrotuberculosis].

  Urologiia (Moscow, Russia : 1999) 20060101

• A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.

  TheScientificWorldJournal 20060101

• Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?

  Ophthalmology 20051201

• Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.

  The Journal of urology 20051101

• Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.

  Urology 20051001

• Effects of different alpha-1 adrenoceptor blockers on proximal urethral function using in vivo isovolumetric pressure changes.

  Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi 20051001

• The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.

  BJU international 20050901

• Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.

  Urology 20050801

• Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.

  The Canadian journal of urology 20050801

• Re: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.

  The Journal of urology 20050701

• Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.

  BJU international 20050501

• Clinical assessment of drug-induced QT prolongation in association with heart rate changes.

  Clinical pharmacology and therapeutics 20050401

• Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.

  BJU international 20050301

• Re: alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.

  The Journal of urology 20050301

• The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study.

  European urology 20050301

• Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays.

  The Journal of pharmacology and experimental therapeutics 20050201

• Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.

  Urology 20050101

• [The role of alpha1-adrenoblocker alfuzosine in diagnostic-therapeutic algorithm of hyperactive urinary bladder management in women and selection of patients for treatment with M-cholinergic antagonists].

  Urologiia (Moscow, Russia : 1999) 20050101

• A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial.

  The Journal of international medical research 20050101

• Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*.

  International urology and nephrology 20050101

• Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.

  Clinical therapeutics 20041101

• Alfuzosin-induced acute hepatitis in a patient with chronic liver disease.

  The Annals of pharmacotherapy 20040901

• Prostate size influences the outcome after presenting with acute urinary retention.

  BJU international 20040901

• New drugs 04. Part III.

  Nursing 20040901

• Ejaculatory dysfunction and alpha-adrenoceptor antagonists.

  BJU international 20040801

• [A suggested treatment algorithm in nocturnal enuresis with emphasis on partial responders].

  Der Urologe. Ausg. A 20040701

• Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.

  The Journal of urology 20040601

• On call. My doctor gave me a prescription for Uroxatral to treat my enlarged prostate. I tried to look up this medicine in your Harvard Medical School Guide to Men's Health, but I couldn't find it. What can you tell me about Uroxatral?

  Harvard men's health watch 20040601

• [The growth inhibition effect of alpha-adrenoceptor antagonists on androgen- independent prostate cancer cell line].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20040522

• Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.

  BJU international 20040401

• Priapism as a possible acute side effect of radical radiotherapy for prostate cancer.

  The Canadian journal of urology 20040401

• A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats.

  BJU international 20040301

• Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.

  The American journal of geriatric pharmacotherapy 20040301

• A current review of medical therapy for benign prostatic hyperplasia.

  The Journal of the American Osteopathic Association 20040201

• Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.

  The Medical letter on drugs and therapeutics 20040105

• Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats.

  European urology 20040101

• [Can selective alpha-blockers help the spontaneous passage of the stones located in the uretero-bladder junction?].

  Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20040101

• A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.

  Scandinavian journal of urology and nephrology 20040101

• Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.

  BJU international 20031201

• Alfuzosin for the management of benign prostate hyperplasia.

  Expert opinion on pharmacotherapy 20031101

• First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.

  Urology 20031101

• [Pharmacologic treatment of benign prostatic hyperplasia].

  Orvosi hetilap 20030914

• Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.

  Urology 20030901

• Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.

  BJU international 20030801

• Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030715

• Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration.

  European urology 20030701

• Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.

  Circulation 20030617

• Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum.

  BJU international 20030601

• Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525

• Current treatment options for benign prostatic hyperplasia and their impact on sexual function.

  Urology 20030401

• Benign prostatic hyperplasia.

  Hospital medicine (London, England : 1998) 20030201

• Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.

  Urologia internationalis 20030101

• Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.

  Journal of clinical pharmacology 20021201

• Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder.

  BJU international 20021101

• Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.

  European urology 20021001

• Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.

  International journal of clinical pharmacology and therapeutics 20020701

• [Chiral separation and preparation of three new antagonists of alpha 1-adrenoceptors by chiral mobile phase HPLC].

  Yao xue xue bao = Acta pharmaceutica Sinica 20020601

• Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.

  The Journal of urology 20020401

• Alfuzosin: a clinically uroselective alpha1-blocker.

  World journal of urology 20020401

• The use of alpha-adrenoceptor antagonists in lower urinary tract disease.

  Expert opinion on pharmacotherapy 20020201

• [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].

  Urologiia (Moscow, Russia : 1999) 20020101

• Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.

  Drugs 20020101

• Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.

  European urology 20020101

• Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.

  Urology 20011201

• Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.

  Urology 20011201

• Worldwide experience with alfuzosin and tamsulosin.

  Urology 20011001

• Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.

  Journal of clinical epidemiology 20010501

• Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.

  Urology 20010301

• Does acute urinary retention respond to alpha-blockers alone?

  European urology 20010301

• The efficacy and safety of a new once-a-day formulation of an alpha-blocker.

  European urology 20010301

• [Long-term therapy of benign prostatic hyperplasia. Our experience].

  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20010301

• alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.

  The Journal of urology 20010101

• A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors.

  Naunyn-Schmiedeberg's archives of pharmacology 20010101

• [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].

  Urologiia (Moscow, Russia : 1999) 20010101

• [Dalphaz-retard treatment of urination disorders in men and women].

  Urologiia (Moscow, Russia : 1999) 20010101

• Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.

  International urology and nephrology 20010101

• Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.

  International urology and nephrology 20010101

• The efficacy of alfuzosin treatment in patients with prostatism.

  International urology and nephrology 20010101

• A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

  European urology 19990101

• [Combined use of 5 alpha-reductase inhibitors and alpha-l adrenergic receptor blockers in patients with benign prostatic hyperplasia].

  Urologiia i nefrologiia 19980101

• Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

  British journal of urology 19971001

• Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes.

  The Prostate 19970915

• Prostatic alpha 1-adrenoceptors and uroselectivity.

  The Prostate 19970215

• Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy.

  European journal of pharmacology 19950116

• [Assessment of the effects of alfuzosin on miction with dynamic echography].

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 19940901

• Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog.

  Urology 19940701

• The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.

  Molecular pharmacology 19940401

• Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.

  Scandinavian journal of urology and nephrology. Supplementum 19940101

• [Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].

  Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma 19940101

• Identification of alpha 1-adrenoceptor subtypes present in the human prostate.

  Life sciences 19940101

• Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.

  British journal of urology 19931201

• The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin.

  International journal of clinical pharmacology, therapy, and toxicology 19931101

• Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract.

  British journal of pharmacology 19930801

• Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

  Drugs 19930301

• [Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 19920301

• Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities.

  European urology 19920101

• Peripubertal changes in the nature of the GnRH response to alpha-adrenoceptor stimulation in vitro and their modulation by testosterone.

  Neuroendocrinology 19900701

• A comparison of the effects of doxazosin and alfuzosin with those of urapidil on preganglionic sympathetic nerve activity in anaesthetised cats.

  European journal of pharmacology 19861007